Information Provided By:
Fly News Breaks for September 12, 2017
CTIC
Sep 12, 2017 | 07:05 EDT
Jefferies analyst Matthew Andrews started CTI BioPharma with a Buy rating and $7.50 price target. The analyst believes pacritinib is an approvable drug in the U.S. and sees "meaningful upside" from current share levels.
News For CTIC From the Last 2 Days
There are no results for your query CTIC